Maryland-based biotechnology company Novavax said its experimental COVID-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to an early stage study
The company said it would likely move forward with the lower of two tested doses of the vaccine. It reported that eight study participants experienced adverse side effects after receiving a second vaccine dose during the trial. The company said none required medical intervention.
Maryland-based Novavax said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients, raising hopes for its eventual success. Effective vaccines and treatments are considered essential to halting a pandemic that has claimed more than 695,000 lives worldwide.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novavax's coronavirus vaccine generates promising immune response in early trial, data showsNovavax's potential vaccine to prevent Covid-19 generated a promising immune response in an early-stage clinical trial, the U.S.-based biotech firm announced Tuesday.
Weiterlesen »
As vaccines move into phase 3 trials, diversity must be at top of agendaEnsuring Black and ethnic minority participation in coronavirus vaccine trials is key if we want a truly effective coronavirus vaccine, according to experts.
Weiterlesen »
Novavax stock: Human results for coronavirus vaccine candidate - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Weiterlesen »
Progress slow on COVID-19 aid bill as negotiations continueProgress is coming slowly as lawmakers craft another major response to the coronavirus pandemic.
Weiterlesen »
How Boom-Bust Vaccine Speculation Kneecapped the U.S. Coronavirus ResponseExecutives at Moderna, a leading contender for a COVID-19 vaccine, have pocketed millions, and the value of biotech companies has exploded. “People feel they can take risks,” says one expert—but for some it could all come crashing down.
Weiterlesen »